Kemper Corp Master Retirement Trust maintained its position in shares of Novartis AG (NYSE:NVS) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,500 shares of the company’s stock at the close of the second quarter. Novartis AG accounts for about 1.3% of Kemper Corp Master Retirement Trust’s investment portfolio, making the stock its 29th biggest holding. Kemper Corp Master Retirement Trust’s holdings in Novartis AG were worth $2,045,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of NVS. City Holding Co. grew its position in Novartis AG by 4.6% during the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after acquiring an additional 54 shares during the last quarter. Archford Capital Strategies LLC grew its position in Novartis AG by 72.3% during the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after acquiring an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC grew its position in Novartis AG by 3.4% during the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after acquiring an additional 49 shares during the last quarter. North Star Investment Management Corp. grew its position in Novartis AG by 1.0% during the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after acquiring an additional 16 shares during the last quarter. Finally, Massey Quick & Co. LLC bought a new position in Novartis AG during the first quarter valued at approximately $119,000. Institutional investors and hedge funds own 10.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/08/kemper-corp-master-retirement-trust-continues-to-hold-holdings-in-novartis-ag-nvs.html.

Novartis AG (NVS) traded up 0.15% during mid-day trading on Friday, hitting $85.77. The stock had a trading volume of 818,819 shares. The stock’s 50-day moving average price is $84.84 and its 200-day moving average price is $81.39. The stock has a market cap of $200.95 billion, a price-to-earnings ratio of 31.31 and a beta of 0.73. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90.

Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. On average, analysts predict that Novartis AG will post $4.75 earnings per share for the current year.

A number of research analysts have commented on NVS shares. Zacks Investment Research cut shares of Novartis AG from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, August 29th. Credit Suisse Group cut shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target on the stock. in a research report on Wednesday, July 5th. Morgan Stanley upgraded shares of Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. Finally, Leerink Swann reiterated a “market perform” rating and set a $83.00 price target on shares of Novartis AG in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $85.12.

Novartis AG Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.